Skip to main content

Tranzyme and BD Technologies Strike Deal to Share Lab Space, Technology

NEW YORK, Sept. 10-Tranzyme has launched a research collaboration with BD Technologies, the two companies said today. Tranzyme also said today that it will also open a new lab for neurosensory disease research in BD Technologies' Research Triangle Park incubator.

 

For the research collaboration, Tranzyme will provide its gene transfer and protein expression technologies, which BD Technologies will use in specific cell lines for drug discovery, cell and tissue engineering.

 

BD has the right to market commercial products generated through this agreement, and will pay fees to Tranzyme for product sales. Tranzyme will have access to other BD Technologies intellectual property for its own drug development efforts in sensory system disease, as well as assistance in developing new collaborations with other divisions of BD.

 

Tranzyme expects that its new Research Triangle Park labs will allow the company to develop new collaborations with biotech companies in the area.

 

Tranzyme, which is based in Birmingham, Ala., focuses on genomics-based treatment for sensory diseases, neurodegenerative disease and viruses like HIV.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.